[Webinar] Epigenetic Reactivation for X-Linked NDDs

Kyle Fink, PhD is a Ladder Rank Associate Professor at the Department of Neurology at University of California, Davis. The Fink laboratory focuses on the therapeutic development of gene modifying modalities such as Zinc Fingers, Transcription Activator-like Effectors, and CRISPR/Cas9 to treat genetically-linked neurological disorders. His unique academic training and research experience have provided him with an excellent background in multiple biological disciplines including neuroscience, molecular biology, microbiology, chemistry, and genetics. His lab is focused on translating novel gene modifying therapeutics using patient-derived human iPSC, transgenic rodents, and large animals (macaques) for translation. His lab focuses on the therapeutic development of gene modifying modalities to induce epigenetic alterations in neurodegenerative and neurodevelopmental disorders for which there is known genetic etiology. Their group also focuses on the optimization of delivery modalities, such as viral vectors, lipid nanoparticles and hemopoietic blood and mesenchymal stem cells. The Fink laboratory has focused on developing…